RxDoctor Payments Data

Christina Schuck

Family · Fairfield, ILNPI 1891248423

Payments from drug & device makers

$1,386in general payments, 2019–2025

Across 78 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$437
  • Lilly USA, LLC$179
  • Novo Nordisk$154
  • Pfizer$135
  • Organon$130
  • Sanofi-aventis U.S. LLC$86
  • plus $266 from 10 others

What the payments were for

  • Food & beverage$1,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,386 in reported general payments places this provider in the 75th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$2,441
Medicare patients
51
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$28,603
TrulicityDulaglutide20$28,003
JardianceEmpagliflozin24$19,886
FarxigaDapagliflozin Propanediol12$14,331
TradjentaLinagliptin14$10,981
VascepaIcosapent Ethyl12$8,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,023
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen54$2,003
Levothyroxine Sodium110$1,742
Novolog FlexpenInsulin Aspart11$1,501
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$1,448
Cyclobenzaprine Hcl87$1,202
Potassium Chloride66$1,150
Gabapentin70$1,143
Omeprazole85$1,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$25$30,86638 claims
PfizerEliquis$135$28,60331 claims
Lilly USA, LLCTrulicity$179$28,00320 claims
AstraZenecaFarxiga$437$14,33112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,941 family providers in Illinois.

Other family in Fairfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →